Sosei Heptares Enters R&D Agreements with the University of Oxford and KU Leuven to Identify and Validate Key GPCRs Driving Gastrointestinal and Immune Disorders
08 déc. 2022 01h30 HE
|
Sosei Group Corporation
Agreements build on Sosei Heptares’ Target Identification and Validation strategy and translational medicine approach to drug discovery, enabling the Company to rapidly prioritize disease-relevant...
Sosei Heptares Operational Highlights and Consolidated Results for the Third Quarter and First Nine Months of 2022
11 nov. 2022 01h30 HE
|
Sosei Group Corporation
TOKYO and CAMBRIDGE, United Kingdom, Nov. 11, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated...
Sosei Heptares’ President & CEO and Head of UK R&D to Participate in a ‘Fireside Chat’ at the Jefferies London Healthcare Conference 2022
09 nov. 2022 03h00 HE
|
Sosei Group Corporation
TOKYO and CAMBRIDGE, United Kingdom, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565) announces its President & CEO Chris Cargill and Matt Barnes, Head of UK...
Sosei Heptares’ Partner Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1117568 in Adults with Schizophrenia
27 oct. 2022 19h05 HE
|
Sosei Group Corporation
NBI-1117568 is an Investigational, First-in-Class, Muscarinic M4 Selective Agonist TOKYO and CAMBRIDGE, United Kingdom, Oct. 28, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”;...
Sosei Heptares to host R&D Day highlighting its innovative R&D and translational medicine approaches to drug discovery and strong pipeline momentum
27 sept. 2022 02h30 HE
|
Sosei Group Corporation
TOKYO and CAMBRIDGE, United Kingdom, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565) will hold an R&D Day on Thursday, 13 October 2022, at 3:30 pm JST. The...
Sosei Heptares Wins Licensing Deal of the Year and Executive of the Year at the Inaugural Informa Pharma Intelligence Awards Japan
01 sept. 2022 19h05 HE
|
Sosei Group Corporation
TOKYO and CAMBRIDGE, United Kingdom, Sept. 02, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565), an international biopharmaceutical company and world-leader in...
Sosei Heptares Operational Highlights and Consolidated Results for the Second Quarter and First Half of 2022
10 août 2022 02h45 HE
|
Sosei Group Corporation
TOKYO, Japan and CAMBRIDGE, United Kingdom, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565) provides an update on operational activities and reports its...
Sosei Heptares’ Oral, Selective M4 Receptor Agonist Advancing into Phase 2 Clinical Development under Multi-Program Collaboration with Neurocrine Biosciences
04 août 2022 19h05 HE
|
Sosei Group Corporation
Neurocrine to conduct placebo-controlled Phase 2 study to investigate NBI-1117568 (formerly HTL-0016878) as a potential new treatment for schizophrenia Clinical development milestone triggers payment...
Sosei Heptares and AbbVie Enter New Multi-target Collaboration to Discover, Develop and Commercialize Novel Medicines Targeting Neurological Diseases
01 août 2022 19h05 HE
|
Sosei Group Corporation
New strategic collaboration leverages Sosei Heptares’ StaR® technology and SBDD platform and AbbVie’s extensive neuroscience expertise Second collaboration with AbbVie follows 2020 agreement focused...
Cancer Research UK and Sosei Heptares sign agreement to advance cancer immunotherapy candidate into clinical trials
21 juil. 2022 19h05 HE
|
Sosei Group Corporation
TOKYO, Japan and LONDON and CAMBRIDGE, United Kingdom, July 22, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565), an international biopharmaceutical company and...